Signed 29.5 Billion KRW Export Contract with M8
"High Growth Potential for Premium Toxin Market"

Daewoong Pharmaceutical announced on January 30 that it has signed an export contract for Nabota worth 29.5 billion KRW with M8 (Moksha8) for the Mexican market.


With this contract, Nabota has successfully entered all of the top five aesthetic and plastic surgery markets in Latin America, according to International Society of Aesthetic Plastic Surgery (ISAPS) statistics, including Mexico, Brazil, Argentina, Colombia, and Chile.

Daewoong Pharmaceutical Nabota. Daewoong Pharmaceutical

Daewoong Pharmaceutical Nabota. Daewoong Pharmaceutical

View original image

Since starting with Panama in 2015, Daewoong Pharmaceutical has continued to expand Nabota into major Latin American markets such as Brazil, Argentina, Colombia, Peru, and Chile. To date, the company has signed export contracts in 17 out of 20 Latin American countries, with products launched in 13 of these markets.


Based on its strong partnership with M8, Daewoong Pharmaceutical is set to accelerate its efforts to penetrate the key aesthetic and plastic surgery market of Mexico. Drawing on its successful experience in Brazil, the company plans to create new growth momentum in Mexico?where three leading global brands account for more than 95% of the market share?by operating a specialized sales organization, actively expanding sales channels, implementing systematic training programs for local medical professionals, and enhancing customer loyalty strategies.


Since 2018, M8 has collaborated with Daewoong Pharmaceutical to successfully launch Nabota in the Brazilian market. While focusing on the highly competitive dermatology and plastic surgery sectors, M8 strategically prioritized the aesthetic and dental clinic markets, which have high growth potential. In just over five years since the launch, the contract volume has increased more than tenfold, and recently, the partnership was further strengthened with a Nabota supply contract worth approximately 180 billion KRW.



Yoon Joonsoo, Head of the Nabota Business Division at Daewoong Pharmaceutical, stated, "Mexico is the second largest aesthetic and plastic surgery market in Latin America after Brazil, making it a key strategic country in terms of market size. Although the frequency of aesthetic procedures per capita is still lower than in Korea, the market has significant growth potential and a high potential for the premium toxin segment, making it a very attractive market."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing